Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Daniel Judge, MD
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40%
Javed Butler, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Kevin Alexander, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Amy Mottl, MD, MPH
Muthiah Vaduganathan, MD, MPH
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Ahmad Masri, MD, MS
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Prof. Christoph Wanner
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
When and Why to Use CAC Scoring
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
Target in Sight: Escalating Therapy to Reach LDL-C Goals
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Statins and Safety: What the Data Say About Dementia, Cancer, and More
Bridging ASCVD Care Between Academic and Rural Settings
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
From Risk to Results: Cases in ASCVD Prevention and Treatment
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.